SCHEMBL30041909

SCHEMBL30041909

N#Cc1cccc(-c2noc(N)n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.57
CHRNB2 P17787 1/20 0.57
CHRNA5 P30532 1/20 0.57
CHRNA4 P43681 1/20 0.57
CLK4 Q9HAZ1 3/20 0.54
GRM5 P41594 1/20 0.52
ADORA2A P29274 4/20 0.48
ADORA1 P30542 4/20 0.48
ADORA3 P0DMS8 1/20 0.46
CYP1A2 P05177 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
CYP3A4 P08684 3/20 0.46
MAPK1 P28482 2/20 0.46
CYP2C19 P33261 2/20 0.46
ALDH1A1 P00352 2/20 0.46
XDH P47989 1/20 0.46
S1PR3 Q99500 1/20 0.46
LMNA P02545 2/20 0.45
TP53 P04637 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23539548 1.00 NOTUM (0.57) NOTUMCHRNB2CHRNA5CHRNA4CLK4
SCHEMBL13130237 0.81 L3MBTL1 (0.70) NOTUMCHRNB2CHRNA5CHRNA4CLK4
SCHEMBL12704747 0.81 CHRNB2 (0.53) NOTUMCHRNB2CHRNA5CHRNA4CLK4
SCHEMBL29463424 0.79 CHRNB2 (0.54) NOTUMCHRNB2CHRNA5CHRNA4CLK4
SCHEMBL24660518 0.79 CHRNB2 (0.54) NOTUMCHRNB2CHRNA5CHRNA4CLK4
SCHEMBL23539722 0.78 CHRNB2 (0.53) NOTUMCHRNB2CHRNA5CHRNA4CLK4
SCHEMBL30041989 0.78 CHRNB2 (0.53) NOTUMCHRNB2CHRNA5CHRNA4CLK4
SCHEMBL1545138 0.78 CHRNB2 (0.53) NOTUMCHRNB2CHRNA5CHRNA4CLK4
SCHEMBL2476819 0.77 CLK4 (0.71) NOTUMCHRNB2CHRNA5CHRNA4CLK4
SCHEMBL11938358 0.76 CLK4 (0.69) NOTUMCHRNB2CHRNA5CHRNA4CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115279741-A 4-phenyl-N- (phenyl) thiazol-2-amine derivatives and related compounds as Aryl Hydrocarbon Receptor (AHR) agonists for the treatment of, for example, angiogenesis-related disorders or inflammatory disorders 医肯纳肿瘤学公司 2022-11-01 CN disclosed